09 June 2000

                    PROFESSIONAL SERVICES and CONFIDENTIALITY
                                AGREEMENT between
                                   Lexon, Inc.
                                        &
                          DIAGNOSTIC ONCOLOGY CRO, Inc.




                                     PARTIES

The parties to this  Professional  Services and  Confidentiality  Agreement  are
Lexon,  Inc. and its affiliates,  subsidiaries and the like ("LEXON") located in
Tulsa,  Oklahoma,  and  DIAGNOSTIC  ONCOLOGY  CRO,  Inc.  ("DOCRO"),  located in
Seymour, Connecticut.



                                    PURPOSES

LEXON is engaged in the business of developing medical  diagnostic  products for
distribution  to the  biotechnology,  healthcare,  medical  diagnostic,  medical
device, and therapeutic  industries,  in particular,  in vitro diagnostic assays
for determining the presence of telomerase in the blood,  other body fluids, and
other specimen matrices of mammals.

DOCRO is engaged in providing technology assessment, technology development, and
laboratory  and  clinical  trial  services  to  medical  device  developers,  in
particular,  providing technology assessment and technology development services
related to the development and  commercialization  of in vitro diagnostic assays
for  determining  the amount of tumor markers or other  analytes in the tissues,
blood, other fluids, and other specimen matrices of mammals.

LEXON wishes to engage DOCRO to conduct a technology  assessment and development
program for LEXON's  telomerase tumor marker  technology.  This program requires
DOCRO to assess the current  technical and clinical  performance of the existing
telomerase reagents as provided by Dr. H. E. Highsmith,  University of Maryland,
Baltimore,  then for DOCRO to develop or procure  purified  telomerase  antigens
(including  various peptides and, if possible,  native and recombinant  protein,
for known forms of telomerase  protein/nucleic acid complex) expressed in humans
and then to raise or procure a variety of monoclonal  antibodies  and polyclonal
antibodies to these various  antigens to determine if any telomerase  antigen is
overexpressed  in the  tissue,  blood,  other body  fluids,  and other  specimen
matrices  from humans  diagnosed  with lung or other  cancers  when  compared to
similar specimens from apparently healthy, normal humans and



                                   --1 of 14--

<PAGE>


from a variety of humans diagnosed with other non-malignant  diseases.  Further,
if a telomerase  antigen is determined by DOCRO to be overexpressed in malignant
disease and not in non-malignant disease or apparently healthy normals and LEXON
agrees, DOCRO shall develop an enzyme immunoassay for such telomerase antigen to
confirm  the  results  in  the  blood  or  other  fluid  specimen  matrix  of  a
statistically significant number (maximum of 400) patients.

In consideration of the mutual promises specified below, DOCRO offers to provide
technology assessment and technology development  professional services to LEXON
in  accordance  with the terms and  conditions  of this  Agreement,  which LEXON
accepts.




                                   DEFINITIONS

"Confidential & Proprietary  Information" shall include any information owned by
any party, as well as information developed by DOCRO in connection with services
performed  under this Agreement which shall be considered  LEXON's  confidential
information,  whether or not such information is in oral, written or other form,
or was  denominated or specifically  identified as confidential  when disclosed,
observed or  developed.  Such  information  may  include,  but is not limited to
commercial or  technological  plans,  customer lists,  discoveries,  inventions,
know-how,  processes,  software,  suppliers,  trade  secrets,  as  well  as  any
analytical chemical or biological specimens or prototypes.

"DOCRO" shall mean the entity  identified in the PARTIES section,  including any
entities affiliated with DOCRO,  including but not limited to DOCRO's employees,
agents, officers or principals, and, its contractors.

"LEXON" shall mean the entity  identified in the PARTIES section,  including any
entities affiliated with LEXON (or any purchaser of substantially all of LEXON's
assets),  including but not limited to LEXON's  employees,  agents,  officers or
principals, and, its contractors.

"PRODUCTS"  shall mean LEXON's  telomerase  technology  used for the  assessment
and/or  development  of an  in  vitro  diagnostic  assay  to  determine  if  any
telomerase antigen is overexpressed in the tissue, blood, other body fluids, and
other  specimen  matrices from humans  diagnosed with lung or other cancers when
compared to similar specimens from apparently healthy,  normal humans and from a
variety of humans  diagnosed with other  non-malignant  diseases,  including any
native or  recombinant  telomerase  protein or peptide  antigen in any form, and
antibody  raised to any  native or  recombinant  telomerase  protein  or peptide
antigen.



                                   --2 of 14--

<PAGE>


                              TERMS AND CONDITIONS


1.0   Services to be Provided by DOCRO

1.1. Technology  Assessment - DOCRO shall assess for LEXON the current technical
and  clinical  performance  of the existing  telomerase  reagents as provided by
LEXON and the inventor, Dr. H. E. Highsmith, University of Maryland, Baltimore.

1.2. Technology  Development -DOCRO shall develop or procure purified telomerase
antigens  (including  various peptides and, if possible,  native and recombinant
protein,  for known forms of telomerase  protein/nucleic acid complex) expressed
in humans and then to raise or procure a variety of  monoclonal  antibodies  and
polyclonal  antibodies to these various  antigens to determine if any telomerase
antigen is  overexpressed  in the tissue,  blood,  other body fluids,  and other
specimen matrices from humans diagnosed with lung or other cancers when compared
to similar specimens from apparently  healthy,  normal humans and from a variety
of humans diagnosed with other non-malignant diseases.  Further, if a telomerase
antigen is determined by DOCRO to be overexpressed in malignant  disease and not
in non-malignant  disease or apparently healthy normals and LEXON agrees,  DOCRO
shall develop an enzyme  immunoassay for such telomerase  antigen to confirm the
results  in  the  blood  or  other  fluid  specimen  matrix  of a  statistically
significant number (maximum of 400) patients.

1.3. Analysis and Reports - DOCRO shall provide to LEXON an analysis and written
report of the work performed with recommendations for the next steps to be taken
by DOCRO  conducted in Section  1.1. and Section 1.2. on a bi-weekly  basis from
the inception of the project.  LEXON must provide written  notification to DOCRO
within  forty-eight  (48) hours of the  issuance of the report if LEXON  desires
DOCRO not to perform the work that DOCRO  recommends in the report.  DOCRO shall
provide to LEXON a written report  summarizing  DOCRO's  findings and activities
upon DOCRO's  completion of the technology  assessment portion of this Agreement
and upon termination of this Agreement.

1.4. The parties agree that DOCRO shall  provide  LEXON with its services  under
this  Agreement on a  non-exclusive  basis.  Subject to the  limitations of this
Agreement,  DOCRO and LEXON  may  provide  or  obtain  consulting  and  advisory
services to or from any third party.

1.5.  Pursuant  to the  terms  of this  Agreement,  DOCRO  shall  commence  work
immediately upon receipt of a fully executed  original of this Agreement and the
initial moneys set forth herein.


2.0 Term

2.1.  The term of this  Agreement  shall  commence  on 09 June  2000,  and shall
continue for a duration of two (2) years,  but after  DOCRO's  completion of the
technology  assessment  portion of this  Agreement  may be terminated at will by
LEXON giving thirty (30) days written notice to



                                   --3 of 14--

<PAGE>


the other.  In the event of such  termination,  LEXON's sole obligation to DOCRO
shall be to pay DOCRO any fees and expenses for services  either (i) rendered by
the date of termination including any and all non-refundable prepayments made by
LEXON  to  DOCRO  according  to the  terms  of this  Agreement  or (ii) at least
partially  rendered  and  committed  with  respect  to any case  report  from an
investigator working for DOCRO.

2.2. The confidentiality  provision of Section 4.0 of this Agreement shall be in
force for a period of three (3) years from the effective date of this Agreement.


3.0 Compensation & Reimbursement

3.1. DOCRO shall be compensated by LEXON  according to the terms of the attached
schedule (see  Attachment A. - Estimated Fees,  Milestone and Payment  Schedule)
and this Section 3.0 for the conduct of the technology assessment and technology
development professional services rendered by DOCRO under the provisions of this
Agreement.

3.3.  DOCRO  shall be  compensated  by LEXON for the  conduct of the  technology
assessment  and  technology  development  professional  services in total of one
million,  eight  hundred,   fifty-eight  thousand,   nine  hundred  dollars  (US
$1,858,900.00).  The first two (2) fully creditable and non-refundable  payments
to DOCRO  totaling five hundred,  fifty  thousand  dollars (US  $550,000.00)  as
described  in  this  section  of the  Agreement  and in any  attachment  to this
Agreement are made to DOCRO for the conduct of the technology assessment portion
of this  Agreement.  The first  payment  to DOCRO  shall be a fully  creditable,
non-refundable  advance  payment of two  hundred,  fifty  thousand  dollars  (US
$250,000.00) upon execution of this Agreement. The second payment to DOCRO shall
be a fully creditable,  non-refundable payment of three hundred thousand dollars
(US  $300,000.00)  sixty (60) days after the date of execution of this contract.
The basis for these amounts and the dates for additional  payments to be made by
LEXON to DOCRO are set forth in  Attachment A. - Estimated  Fees,  Milestone and
Payment  Schedule.  Such payments shall be made by wire transfer to DOCRO's bank
account:  People's Bank of Connecticut,  Bridgeport,  Connecticut - Bank Routing
Number 221172186,  Account Number  014-7006302.  The aggregate amount of the two
advance payments,  five hundred, fifty thousand dollars (US $550,000.00),  shall
be subtracted from the total payment due to DOCRO hereunder.

3.3.  DOCRO shall bill LEXON for the  remaining  balance of one  million,  three
hundred  eight  thousand,  nine  hundred  dollars  (US  $1,308,900.00)  plus any
additional expenses approved by LEXON and incurred as described in Attachment A.
- Estimated Fees,  Milestone and Payment Schedule for services  rendered on this
contract shall be billed to LEXON  according to Attachment A., such monies to be
used by DOCRO for the assay development  portion of this Agreement.  LEXON shall
reimburse DOCRO on a net fifteen (15) day basis, time commencing from submission
to LEXON of invoice and  statement of work  completed or expenses  incurred.  If
timely  payment for invoiced  fees is not made,  in addition to other  remedies,
DOCRO may impose and LEXON  shall pay, a late  payment  charge  equal to one and
one-half percent (1.5%) of the overdue amount each month.


                                   --4 of 14--

<PAGE>


3.4.  DOCRO will notify  LEXON in writing  within five (5) working days from the
effective  date if the estimated  fees and expenses for this project  exceed one
million,  eight  hundred,   fifty-eight  thousand,   nine  hundred  dollars  (US
$1,858,900.00)  (Fee Cap),  including  expenses  described  in  Attachment  A. -
Estimated Fees,  Milestone and Payment  Schedule,  but not including  additional
expenses,  in which case LEXON may terminate the Agreement.  DOCRO shall provide
LEXON a written Project  Description & Estimate (PDE) describing the new aspects
or tasks  required to complete  the  project.  The Fee Cap shall not include any
fees or expenses  applicable  to any meeting with any person or group other than
meetings  with LEXON or with Dr. H.E.  Highsmith  to review work  performed  and
planned  related to the technology  assessment and development of the telomerase
tumor marker technology.

3.5.  DOCRO shall not  initiate  any work the cost of which shall exceed the Fee
Cap prior to obtaining  LEXON's written  approval of a PDE. A PDE shall describe
the aspects of the project to be performed by DOCRO,  including a description of
the specific  personnel and other  resources  needed to perform the new tasks of
the project,  the time or schedule needed to complete such tasks, and a proposed
schedule  for project  related  payments.  The Fee Cap shall be increased by the
amount of any approved PDE.

3.6.  DOCRO  shall  ensure  that all charges  are  allocated  accurately  to the
activity or project for which such charges were  incurred,  and are supported by
documents.  The nature and purpose of all invoiced  items shall be identified in
the supporting documents.

3.7. DOCRO shall be paid for reasonable and necessary business expenses that are
incurred by DOCRO in the course of performing the  obligations of this Agreement
as described  in this  Agreement.  Such costs may include,  (but are not limited
to), the  following:  computer  research;  laboratory  expenses;  long  distance
telephone and telefacsimile charges;  postage, printing and courier charges; and
travel  expenses,  (including  the cost of  transportation,  meals and lodging).
LEXON shall  compensate  DOCRO fully for all travel and living expenses that are
not  described in  Attachment  A. but that either are agreed to by LEXON and are
incurred  for site visits to the premises of LEXON,  any clinical  investigator,
any laboratory investigator,  or any other location that may be requested or are
required  in order  for  DOCRO to  fulfill  its  obligations  described  in this
Agreement.

3.8. The cost to prepare or obtain any reagent,  material, or product by a third
party on behalf of DOCRO and LEXON  shall be passed on to LEXON with an eighteen
percent (18%) additional mark-up by DOCRO.  However,  any equipment,  materials,
consumables,  or non-telomerase  specific reagent paid for by LEXON shall become
the property of DOCRO upon the termination of this AGREEMENT.



                                   --5 of 14--

<PAGE>


4.0 Confidential & Proprietary Information

4.1.  DOCRO and LEXON hereby agree with respect to  Confidential  &  Proprietary
Information:   (1)  to  maintain  the  confidentiality  of  any  Confidential  &
Proprietary Information disclosed; (2) not to make any disclosure of proprietary
or confidential  information to any third party;  (3) not to use  Confidential &
Proprietary  Information except for the Purposes contemplated in this Agreement,
unless such further use is  specifically  authorized in writing by the party who
has  title  to the  information;  (4) to  protect  the  other's  Confidential  &
Proprietary  Information  whether in storage or in use,  with the same degree of
care as is exercised  to protect its own against  public  disclosure  (but in no
case  with  any less  degree  than  reasonable  care);  and (5) not to  disclose
Confidential  & Proprietary  Information  to any personnel  other than those for
whom  such  knowledge  is  essential  for  the  purposes  contemplated  in  this
Agreement,  and such  disclosure to them shall be made only under  conditions of
strict confidentiality.

4.2.  The  obligations  in this  Article  shall  not  apply  to  Confidential  &
Proprietary   Information   that  a  party  can  show  by  previously   existing
documentation:  (a) is in the public domain on the date of this  Agreement;  (b)
comes  into  the  public  domain  other  than  through  that  party's  fault  or
negligence;  (c) is  obtained  lawfully  from a third  party with full rights of
disclosure;  (d) was known  already  to that party at the date of receipt of the
information pursuant to this Agreement;  (e) becomes known independently to that
party without making use of any of the other party's  Confidential & Proprietary
information.

4.3. If this Agreement  expires or is terminated,  then a receiving  party shall
promptly return all  Confidential & Proprietary  Information,  together with all
copies thereof, except for the retention of one copy for archival purposes. Upon
a written request,  the parties shall respectively provide an accounting for the
disposition   of  all  such   documents  or   specimens,   including  a  written
certification  attesting  to return of all such  confidential  information.  The
parties shall return such items regardless of any claims against one another.

4.4.  No party  shall  make any  press  release  or  other  public  announcement
concerning  the terms or  execution  of this  Agreement  without  prior  written
consent of the other parties, which shall not be withheld unreasonably.

4.5. If a disclosure of  Confidential  & Proprietary  Information  prohibited by
this Agreement is specifically required by law or by court order, any party will
notify the other parties of such required disclosure and, if so requested,  will
execute all necessary documents and provide all reasonable  assistance necessary
to defend the other  party's  lawful right to prevent or limit such  disclosure.
The notifying party shall be entitled  reasonable  compensation for assisting in
such a defense.


5.0 Warranties & Certifications

5.1. DOCRO  warrants  that it shall  make  its best  efforts  to  evaluate  and
demonstrate that the



                                   --6 of 14--

<PAGE>


telomerase  technology  performs  technically  and  clinically  as  claimed  and
represented  by  LEXON  and by Dr.  H. E.  Highsmith,  University  of  Maryland,
Baltimore.  By 25 June 2000, LEXON shall deliver to DOCRO a document  containing
those claims and  representations.  However,  DOCRO does not guarantee  that the
current  telomerase  reagents or assay as run in DOCRO's laboratory will meet or
exceed the performance claims asserted by LEXON or by Dr. H. E. Highsmith.

5.2.  DOCRO does not  guarantee  that the  telomerase  reagents  and assay to be
developed  by DOCRO under the terms of this  Agreement  shall meet or exceed the
claims of LEXON nor does DOCRO  guarantee that the developed assay shall provide
sufficient  technical or clinical  performance  characteristics  nor  sufficient
clinical  sensitivity and specificity to warrant additional assay development or
subsequent  clinical trials,  including any trial intended for submission to the
U.S.  Food and  Drug  Administration  for  LEXON to gain  approval  to  market a
telomerase assay in the United States of America.

5.3. DOCRO certifies that all of its employees, agents and contractors are bound
by the provisions of this  Agreement,  that it has obtained  written  agreements
from such  employees  and agents  that are  consistent  with the  provisions  of
Section 4.0 of this Agreement,  and that it will obtain written  agreements from
employees,  agents and contractors who in the future will become associated with
the project contemplated in this Agreement.

5.4.  DOCRO  represents  and certifies that it and its employees and agents have
all appropriate expertise, training, certifications, immunizations and equipment
to safely and lawfully  handle any materials,  perform any laboratory  tests, or
enter into work  areas  which may be  necessary  for work  performed  under this
Agreement.

5.5. LEXON certifies that all of its employees, agents and contractors are bound
by the provisions of this  Agreement,  that it has obtained  written  agreements
from such  employees  and agents  that are  consistent  with the  provisions  of
Section 4.0 of this Agreement,  and that it will obtain written  agreements from
employees,  agents and contractors who in the future will become associated with
the project contemplated in this Agreement.

5.6. LEXON warrants that no danger, hazard, or the like is known with respect to
its PRODUCTS,  other than those dangers known to be associated  with  infectious
blood samples.

5.7.  LEXON  and  DOCRO  warrant  that the  signatories  to this  Agreement  are
authorized to execute this Agreement on behalf of the respective parties.


6.0   Modification of Agreement

6.1. No waiver or modification of this Agreement shall be valid, nor shall it be
offered or received in evidence in any  proceeding,  arbitration  or  litigation
between the parties  arising  out of or related to this  Agreement,  unless such
waiver or  modification  is in writing signed by authorized  representatives  of
both parties,  particularly pointing out any provisions to be added, deleted, or
modified.


                                   --7 of 14--

<PAGE>


6.2. Unless  expressly  approved by the waiving party in accordance with Section
6.1.,  the failure of either party to enforce any  provision  of this  Agreement
shall not be  construed  as a waiver or  limitation  of that  party's  rights to
subsequently  enforce and compel strict  compliance  with every provision of the
Agreement.  No waiver (express or implied) by either party of any breach of this
Agreement shall constitute a waiver of any other or subsequent breach.


7.0 Assignment

This Agreement  shall be binding on and inure to the benefit of each party,  its
successors or assigns.  No assignment  shall be made by either party without the
express  written  consent of the other  party  except that LEXON may assign this
agreement to a purchaser of substantially all of the assets of LEXON.


8.0 Independent Contractor Status

8.1. It is expressly stipulated,  agreed and understood between the parties that
the business  relationship  between DOCRO and LEXON shall be that of independent
contractors,  and does not  constitute a partnership,  joint venture,  agency or
contract of employment.

8.2. No party shall have the authority to make any  statements,  representations
or  commitments  of any kind, or to take any action that shall be binding on the
other,  except as provided for herein or authorized in writing by the parties to
be bound.

8.3.  DOCRO shall be responsible  solely for provision of personnel,  equipment,
and  supplies,  and,  subject  to the terms of this  Agreement,  for  payment of
DOCRO's costs, suppliers,  employees and contractors. In no case shall any party
have the authority,  or represent  themselves as having the  authority,  to bind
legally any other in contract, debt or otherwise.


9.0   Notice

9.1. Any notice  required under this  Agreement  shall be deemed given only upon
receipt of any letter or  instrument  sent by  certified  mail,  return  receipt
requested,  postage prepaid by the sender,  by overnight  courier or by personal
delivery,  unless prior notice is tenured by the sender that a signed  telefaxed
response  followed  by  confirmation  by mail  will  satisfy  the  terms of this
provision.

If to DOCRO:                                   If to LEXON:
------------                                   ------------
Mr. Thomas F. Soriano                          Dr. Thomas R. Coughlin, Jr.
President and Chief Executive Officer          Medical Director
DIAGNOSTIC ONCOLOGY CRO, Inc.                  Lexon, Inc.
73 Cogwheel Lane                               8908 South Yale Avenue, Suite 409
Seymour, CT  06483                             Tulsa, OK  74137-3545


                                   --8 of 14--

<PAGE>


9.3.  From  time to time  either  party,  by  written  notice  to the  other  in
accordance  with this  Section  9.0,  may  designate  different  or  alternative
addresses or manners of delivery that shall become the effective or  alternative
addresses, or manner of delivery, for such party or project as so designated.


10.0   Entire Understanding

This  Agreement  contains the complete  understanding  between the parties as to
conducting  the  technology   assessment  and  technology   development  of  the
telomerase tumor marker technology, but shall not as of the date of execution of
this Agreement,  supersede the agreement between the parties dated 04 April 2000
and its extension dated 18 April 2000.


11.0   Severability

The terms of this Agreement are severable. If any term of this Agreement is held
invalid or unenforceable, the valid and enforceable portion of such term and the
remaining provisions of this Agreement will remain in full force and effect. The
remaining  contract  shall be  interpreted  consistently  with the intent of the
parties with respect to the entire Agreement when the contract was executed.


12.0 Dispute Resolution

12.1.  The  parties  agree  that they will use their  best  efforts  to  resolve
amicably  any  dispute  arising  out  of or  relating  to  this  Agreement.  Any
controversy,  claim or dispute  that cannot be so  resolved  shall be settled by
final  binding  arbitration  in  accordance  with  the  rules  of  the  American
Arbitration  Association  and judgment upon the award rendered by the arbitrator
or arbitrators may be entered in any court having jurisdiction thereof. Any such
arbitration  shall be conducted in  Connecticut.  Within one (1) month after the
commencement  of the  arbitration,  each party shall select one person to act as
arbitrator,  and the two arbitrators so selected shall select a third arbitrator
within one (1) month of their  appointment.  The  Arbitration  Period  shall not
exceed three (3) months. Each party shall bear its own costs and expenses and an
equal share of the arbitrator's expenses and administrative fees of arbitration.

12.2.  This Agreement  shall be governed by and construed in accordance with the
laws of the State of Connecticut, without consideration of choice of law.



                                   --9 of 14--

<PAGE>


13.0.  Headings

The headings  contained in this  Agreement are only for the  convenience  of the
parties and are not to be construed as a  substantive  provision and will not in
any manner affect the interpretation of this Agreement.


The parties execute this Agreement in accordance with all of the above terms and
conditions.


For Lexon, Inc.:

By: /s/ THOMAS R. COUGHLIN                  Date: June 21, 2000
    ----------------------------                  --------------------
      Signature

      Thomas R. Coughlin, Jr., M.D.
      Medical Director



For DIAGNOSTIC ONCOLOGY CRO, Inc.:

By: /s/ THOMAS F. SORIANO                   Date: Friday, 09 June 2000
    ----------------------------                  --------------------
      Signature

      Thomas F. Soriano
      President and Chief Executive Officer


                                  --10 of 14--


<PAGE>


ATTACHMENT A. - Estimated  Fees,  Milestones and Payment
Schedule - Lexon,  Inc. - Telomerase  Technology  Assessment and
Development Project


Work to be Performed by DOCRO


1.   DOCRO shall assess the technical and clinical  performance  characteristics
     of the currently existing telomerase reagents (raw, partially purified,  or
     purified  telomerase  peptides or proteins  (native or recombinant) and any
     antibody  thereto) provided to DOCRO by Dr. H.E.  Highsmith,  University of
     Maryland,  Baltimore, LEXON, or other source to determine if any telomerase
     antigen is  overexpressed  in humans  diagnosed  with lung or other cancers
     when  compared to humans  diagnosed  with a disease other than cancer or to
     apparently healthy, normal humans.

2.   If one or more telomerase  antigens meets the  specifications in 1., above,
     DOCRO shall develop and/or refine telomerase  antibody and antigen reagents
     with  which  DOCRO  shall  develop  and  then   characterize  a  microtiter
     plate-based  enzyme  immunoassay to determine the amount of that particular
     telomerase antigen in the blood or other fluid matrix of human subjects.

3.   DOCRO shall  contract  with,  manage,  oversee,  and  coordinate  all other
     contractors and subcontractors who provide any material prepared or service
     required under the terms of this Agreement.

4.   DOCRO  shall  provide  to LEXON on a  bi-weekly  basis  written  reports of
     DOCRO's  progress  and  recommendations  for the next segment of work to be
     performed.   LEXON  must  provide  written  notification  to  DOCRO  within
     forty-eight (48) hours of the issuance of the report if LEXON desires DOCRO
     not to perform the work that DOCRO recommends in the report.

5.   DOCRO shall provide to LEXON a written report summarizing  DOCRO's findings
     and activities upon DOCRO's completion of the technology assessment portion
     of this Agreement and upon termination of this Agreement.



                                  --11 of 14--

<PAGE>

<TABLE>
<CAPTION>


A. ESTIMATED Milestone and Payment Schedule:

<S>                                                                                     <C>                  <C>


                                                                                       ESTIMATED     MILESTONE Payment Made by Lexon
Milestone                                                                        Completion Date     and Received by DOCRO

1.  LEXON and DOCRO EXECUTE CONTRACT/First Payment                                  12 June 2000     US $  250,000.00

2.  DOCRO hires Frank Wilkinson, Ph.D. as Project Director                          14 June 2000

3.  Project Meeting with Dr. J.E. Highsmith to Launch Project                        16 Jun 2000

3.  Transfer of portion of telomerase peptides, proteins, and antibodies             25 Jun 2000
    from Dr. Highsmith's laboratory to DOCRO's laboratory

5.  Laboratory Work at DOCRO commences and continues through project                 25 Jun 2000
       a.  Adds first then second bench staff personnel                              17 Jul 2000
       b.  Interview and selection of contractor(s) for development and              17 Jul 2000
           Production of peptides and polyclonal and monoclonal antibodies
       c.  Initiate purification of native telomerase                                21 Jul 2000
       d.  Acquire fresh frozen tumor and clinical sample sets from                      ONGOING
           colorectal cancer patients
       e.  Characterize reagents produced by Dr. Highsmith or other source           12 Aug 2000     US $  300,000.00
           - chromatography, electrophoresis/blotting, etc.
       f.  Testing clinical sample sets (cancer, normal, benign)                         ONGOING
       g.  Initiate expression cloning of telomerase                                 14 Sep 2000

6.  DOCRO and contractor(s) prepare peptides for Mab and Pab contractor(s)           28 Jul 2000

7.  DOCRO completes selection and purification of native/recombinant                 30 Nov 2000
    telomerase proteins, ships sufficient quantities to Mab and Pab contractor(s)

8.  DOCRO receives first bleeds of Pab's to peptides; purify/test                    13 Oct 2000

</TABLE>


                                  --12 of 14--

<PAGE>

<TABLE>
<CAPTION>

          <S>                                                                           <C>             <C>


9.  DOCRO receives second bleeds of Pab's to peptides; purify/test                   03 Nov 2000     US $  400,000.00
    DOCRO receives first Mab's to peptides; purify/test

10. DOCRO receives third bleeds of Pabs to peptides; purify/test                     17 Nov 2000

11. DOCRO optimizes EIA sandwich assay using peptide antigen(s)                      26 Jan 2001     US $  400,000.00
    and antibodies thereto, then test clinical samples

11. DOCRO receives first bleeds of Pab's to proteins; purify/test                    09 Feb 2001

12. DOCRO receives second bleeds of Pab's to proteins; purify/test                   23 Feb 2001
    DOCRO receives first Mab's to proteins; purify/test

12. DOCRO optimizes EIA sandwich assay for the form of telomerase                    27 Apr 2001     US $  400,000.00
    antigen overexpressed in lung or other cancers cancer and tests clinical
    samples and compares results with those from EIA using peptide anitgens

12. DOCRO issues written report of findings and recommendations to LEXON             25 May 2001     US $  108,900.00

13. LEXON makes GO/NO GO decision                                                    29 June 2001
------------------------------------------------------------------------------------------------------------------------------------

                                                                  TOTAL                13 MONTHS     US $1,858,900.00


</TABLE>


Comments:

Item 7. - This  assumes  the  concentration  of  telomerase  is greater  than 50
microgram per gram of lung cancer tissue.  If this minimum  concentration is not
achieved,  this  milestone  will depend  solely upon either  peptide  antigen or
recombinant telomerase protein produced by/for DOCRO or Dr. H.E. Highsmith.

Item  12.  - This  milestone  will  be  completed,  most  likely  using  peptide
polyclonal antibodies.


                                  --13 of 14--

<PAGE>

                         TELOMERASE Development Project

                        Lexon Telomerase Proposed Budget




CONFIDENTAL DETAILED INFORMATION




TOTAL - LABOR, LAB, AND MATERIALS - BILLABLE                   $ 1,858,900



                                  --14 OF 14--